HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
1 - 10 of 13
22CT015: CART 19-22 co-administration
This is a Phase 1/2b trial for the treatment of patients with either advanced or refractory B cell Acute Lymphoblastic Leukemia or B-lineage lymphoblastic lymphoma.
AALL1131; A Phase 3 Randomized Trial for HR B-ALL with Dasatinib Arm in Ph-like TKI Sensitive Mutations
The study compares 2 different experimental chemotherapy combinations with the usual chemotherapy combination given during post-Induction therapy.
AALL1521; Ruxolitinib and Chemotherapy for Patients with JAK-Mutant B-ALL
This study is testing the safety and effectiveness of adding a targeted therapy (ruxolitinib) to standard chemotherapy for children, adolescents, and young adults with high-risk acute lymphoblastic leukemia with CRLF2 and other JAK pathway mutations.
Allo CD7 CAR WU-CART-007
The purpose of this study is to determine the safety and tolerability of an experimental form of therapy, known as WU-CART-007 (“study drug”).
Carfilzomib in ALL
This clinical trial is adding the study drug, Carfilzomib, to a standard relapse chemotherapy regimen.
Chemotherapy-induced Nausea and Vomiting Control
The overall goal of this study is to find the best strategies used by parents and patients for managing these symptoms when receiving maintenance therapy.
Humanized CART19 Phase 2 Trial
This purpose of this study is to determine the efficacy of humanized CD19 CAR T cells (huCART19) in pediatric and young adult patients with high-risk relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).
Phase 2 trial of CART19 for Orphan Indications Of Pediatric B Cell Acute Lymphoblastic Leukemia (B-ALL)
This is an open-label, four-cohort, phase 2 study to determine the efficacy of CART19.
This study will determine the safety and usefulness of using the CliniMACS Prodigy platform to manufacture huCART19 cells.
Ribociclib With Everolimus And Dexamethasone For Relapsed ALL
CHOP, in collaboration with Dana-Farber Cancer Institute, is conducting a study for children, adolescents, and young adults up to 31 years old, with relapsed or refractory acute lymphoblastic leukemia. This clinical trial is adding the study drugs ribociclib and everolimus to a standard relapse chemotherapy regimen.